

25 January 2024

RESPIRI SECURES EXCLUSIVE COMMERCIAL LICENSING AGREEMENT FOR CARDIOVASCULAR AI PLATFORM FOR REMOTE PATIENT MONITORING.

Respiri Limited (ASX:RSH; OTCQB:RSHUF) (“Respiri”), an eHealth SaaS Company supporting respiratory healthcare management and remote patient monitoring, is pleased to announce that it has entered into an exclusive RPM commercial licensing agreement with AI and Medical Technology company Echo IQ Limited (ASX: EIQ) by integrating Echo IQ’s AI-backed EchoSolv™ cardiovascular decision support system into Respiri’s remote patient monitoring programs.

Respiri’s Remote Patient Monitoring (RPM) business, being increasingly used in the US by healthcare organisations including, Accountable Care Organisations (ACO) and hospitals, allows Healthcare Providers to provide ongoing patient care continuity and clinical engagement after patient consultation or discharge from hospital. RPM is shown to improve health outcomes reducing unnecessary healthcare expenditure associated with the provision of emergency and other forms of unscheduled care. In recognition of the important role played by high quality RPM, it enjoys CMS (Centers of Medicare and Medicaid Services) reimbursement as well as coverage under private insurance.

Cardiovascular disease is one of the leading causes of hospital admission and readmission in the US. The exclusive addition of EchoSolv™ to Respiri’s RPM solution adds additional strong cardiology capability to an offering already well-established in the monitoring of all chronic conditions. The inclusion of EchoSolv™ into the Respiri RPM suite will not only provide additional business differentiation but will also generate additional revenues from additional RPM services provided and/or from additional revenues that will be generated as part of future risk-share contracts.

Under the terms of the agreement, Respiri will incorporate Echo IQ’s EchoSolv™ cardiovascular solutions into its US RPM value proposition and will pay a monthly license fee for each additional patient identified as meeting current American Heart Association guidelines for severe aortic stenosis as well as heart failure. Pending FDA clearance, Respiri will also pay Echo monthly license royalties for patients identified by Echo IQ’s decision-support platform, EchoSolv™, as displaying high-risk aortic stenosis and heart failure risk profiles, in line with the EchoSolv™ ai algorithms and require RPM to ensure optimum management and minimize the possibility of expensive and often unnecessary hospitalisation. These undiagnosed cardiovascular (CV) patients are at serious risk of expensive medical complications and significantly reduced life expectancies.

Patients with undiagnosed Aortic Stenosis have a poor prognosis including a significantly reduced life expectancy of 18 months and are likely to be admitted into hospital 11 ½ days per annum costing approximately USD12,300 per admission. These patients are a significant cost burden to the healthcare system, and more than half of these patients remain undiagnosed even after diagnostic procedures, such as echocardiography, are conducted. Treatment for such patients is often heart valve replacement surgery, a simple and cost-effective procedure, which reduces patient risk profile to that approaching the general public and significantly reducing the costs associated with these admissions and other associated healthcare services. Respiri sees this analytical diagnostic service utilising existing customer patient echocardiographs as providing potentially significant cost savings to healthcare organisations entering risk-share RPM contracts with the Company and another source of differentiation and additional revenues.

Respiri CEO, Marjan Mikel said “Respiri continues to grow our RPM US business across all chronic conditions, cardiovascular included, and our charter is to continue to build our differentiation with exclusive device portfolio that supports our world class clinical patient engagement. The Echo IQ partnership aligns with this resulting in diagnosing high risk patients who require medical intervention and then ongoing RPM support, all of which is core to us and offered by no other RPM provider. Response to this addition to our services from ACO’s, providers and leading insurers has been very positive and we are confident that this will be added to our service suite with new and existing clients growing our RPM patient pool.

Andrew Grover, Echo IQ CEO said “We are pleased to be working with Respiri on this extension of Echo IQ’s ai-



backed decision support capability in cardiology. The application of our solutions to remote patient monitoring, as well as the insurer and ACO sectors demonstrates the value of our technology in a variety of commercial healthcare settings. We look forward to working with the Respiro team on this opportunity.”

The licensing agreement between Echo IQ and Respiro includes a number of standard commercial terms for a contract of this nature. These include an initial term of 12 months with exclusive rights for the defined territories, as well as minimum sales achievements in order to maintain exclusivity. Should this be achieved, automatic renewal for a further 24 months will be activated.

Approved by the Board of Respiro Limited

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiro Limited
P: +61 408 462 873
E: marjan@respiro.co

Mr Nicholas Smedley
Executive Chairman
Respiro Limited
P: +61 447 074 160
E: nicholas@respiro.co

About Respiro Limited – An RPM Business Augmented by R&D

Respiro Limited (ASX:RSH, OTCQB:RSHUF) is a pioneering presence in the Remote Patient Monitoring (RPM) and MedTech sectors. The company uses its innovative medical device technology with a disruptive business model as an RPM provider to offer the only RPM program with remote wheeze detection for respiratory disorders. As a differentiated RPM provider, Respiro's mission is to improve health outcomes for patients with chronic diseases from cardiovascular, diabetes, obesity and, exclusively, wheeze detection for respiratory disease. Respiro's globally unique medical device and its Remote Patient Monitoring services empower healthcare organisations to take action from patient data when needed, not only when scheduled. Respiro is strategically positioned to revolutionise chronic disease management globally and is focused on the US market, where RPM services qualify for Current Procedural Terminology (CPT) Code reimbursement. Learn more at www.respiro.co/au

About Access Telehealth

Access Telehealth, a Respiro Limited subsidiary, is reshaping chronic care management in the US through best-in-class, patient-centric, reimbursed Remote Patient Monitoring (RPM) solutions. Our clinical team and software platform enable remote care delivery to patients with chronic diseases. The company provides a seamless and timely connection between patients and healthcare providers for better, cost-effective health outcomes. Discover more at www.accessrpm.com

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiro, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiro™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offerings, including wheezo®, visit www.respiro.co/us

Respiro Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiro Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiro current expectations, estimates and projections about the industry in which Respiro operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiro, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiro cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiro only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiro will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.